Moderna Inc. recorded a quarterly loss as vaccine sales waned and the company had an unexpected charge for a canceled ...

Texas Attorney General Ken Paxton has launched an investigation into DeepSeek, the upstart Chinese artificial intelligence ...

MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

Happy V-Day! Gorge on heart-shaped chocolate and ponder the implications of RFK Jr. being sworn in as health secretary. Today, we talk about that, as well as new cancer data from Corbus Pharma, Europe ...

Vaccine maker Moderna had no Valentine’s Day chocolates for investors when its financial results came out Friday. The company ...

A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological ...

Moderna (MRNA), once a pandemic-era darling, has seen its stock plummet 65% over the past year, battered by fading vaccine ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

CFO updates stated that Roivant ended the quarter with $5.2 billion in cash and marketable securities, including $500 million authorized for additional share buybacks and $1 billion in stock ...

Laura is an editor and staff writer at IFLScience. She obtained her Master's in Experimental Neuroscience from Imperial College London.

Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...

Dr. Paulo H. Verardi, a virologist and head of the Department of Pathobiology and Veterinary Science at the University of ...